Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25-positive population

Clin Transplant. Mar-Apr 2011;25(2):E132-5. doi: 10.1111/j.1399-0012.2010.01360.x. Epub 2010 Nov 17.

Abstract

An anti-CD25 monoclonal antibody was added to thymoglobulin for induction therapy in simultaneous pancreas/kidney (SPK) recipients. T-cell subsets including CD3 and CD25 were assessed by flow cytometry analysis in the peripheral blood of SPK (n = 88), and for comparison kidney transplant (KT) recipients were assessed. KT recipients were treated with daclizumab (anti-CD25) alone (five doses; 1 mg/kg) (n = 27) or thymoglobulin alone (4-7 doses; 1 mg/kg) (n = 23). SPK recipients received daclizumab (two doses; 1 mg/kg) in addition to thymoglobulin (five doses; 1 mg/kg). The return of peripheral blood CD25+ cells was delayed for 45 d post-transplantation in the SPK recipients where anti-CD25 was added to thymoglobulin, compared to those KT recipients with thymoglobulin alone. This strategy may result in reduced allogeneic (donor-specific) T effector cells at the time of solid organ transplantation.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum / therapeutic use*
  • Daclizumab
  • Flow Cytometry
  • Humans
  • Immunoglobulin G / therapeutic use*
  • Immunosuppressive Agents / therapeutic use*
  • Interleukin-2 Receptor alpha Subunit / blood*
  • Kidney Transplantation*
  • Lymphocyte Count
  • Pancreas Transplantation*
  • T-Lymphocyte Subsets

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antilymphocyte Serum
  • IL2RA protein, human
  • Immunoglobulin G
  • Immunosuppressive Agents
  • Interleukin-2 Receptor alpha Subunit
  • Daclizumab
  • thymoglobulin